

**Drug Utilization Review Board Meeting
Agenda, Open Session April 20, 2022
10:00 a.m. – 2:00 p.m.**

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

Computer Audio Enabled Zoom Meeting Link: <https://us02web.zoom.us/j/83322810363>

Required Passcode: 122003 Audio Dial in: (312) 626-6799, Meeting ID: 833 2281 0363

Members of the general public are required to complete a conflict-of-interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (April 13, 2022). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD (Chair)
James Backes, PharmD
Gregory Burger, PharmD, CPPS, FASHP, EMT
Daryl J. Callahan, D.O., M.S.S.

Jennifer Clair, MD
Kristen Powell, PharmD
Michele Reisinger, DNP, APRN, FNP-BC
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD

Carol Arace, Administrative Specialist

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Debbie Bruchko, LPN

Christina Faulkner, PharmD, BCPS
Harry Vu, PharmD

MCO Staff

Aaron Dold, PharmD, Sunflower State Health Plan
Mark DeMary, PharmD, Aetna Better Health of Kansas
Sunny Bounyalath, PharmD, UnitedHealthcare Community Plan

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of January 19, 2022 Meeting Minutes

III. NEW BUSINESS

A. New Prior Authorization (PA) Criteria

1. High Cost Compound PA

This PA will be used to increase oversight of APIs used in compounded products.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

B. Revised PA Criteria

1. Ankylosing Spondylitis Agents

This revision includes the addition of Xeljanz®/Xeljanz® XR to the list of agents requiring prior authorization and provides updates to the table of conventional oral agents.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

2. Atopic Dermatitis Agents

This revision includes the addition of Cibinqo™ and Rinvoq® to the list of agents requiring prior authorization and updates to initial and renewal criteria.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

3. Hypercholesterolemia Agents

This revision includes updates to the age groups and dosing information for Repatha®, updates to dosing information for Praluent® and the addition of Leqvio® to the list of agents requiring prior authorization.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

4. Minimum Requirements Prior Authorization

This revision includes updates to several agents and the removal of Onfi®.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

5. Psoriatic Arthritis Agents

This revision includes an update to the indicated age groups and dosing information for Cosentyx® and adds Skyrizi® and Rinvoq® to the list of agents requiring prior authorization.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

C. Tentative Agenda Items (MHMAC and/or PDL Meeting Agenda Items)

1. MHMAC Meeting (April 19, 2022)

- A. ADHD Medications – Safe Use for All Ages
 - Revisit PDMP criteria and management of Qelbree®.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion

- B. Antipsychotic Medications – Safe Use for All Ages
 - Revisit management of Caplyta®.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion

- C. Benzodiazepine Medications – Safe Use for All Ages
 - Revisit PDMP criteria and management of Loreev XR™.
 - c. Prior Authorization Criteria
 - d. Public Comment
 - c. Committee Discussion

IV. ADJOURN

The next DUR Board meeting is scheduled for July 20, 2022.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board’s discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****